Skip to main content
SpringerLink
Log in

Hypertension and Cardiovascular and Lipoprotein Abnormalities in the Polycystic Ovary Snydrome

  • Chapter
Androgen Excess Disorders in Women

Part of the book series: Contemporary Endocrinology ((COE))

  • 1729 Accesses

Abstract

Polycystic ovary syndrome (PCOS) should be considered not only a reproductive problem but a complex, endocrine, multifaceted disease with important health implications. Several lines of evidence suggest an increased cardiovascular risk and cardiovascular disease characterized by impairment of cardiac structure and function, endothelial dysfunction, lipid abnormalities, and chronic low-grade inflammation. All these features are probably linked to the insulin resistance often present in women with PCOS. Cardiovascular abnormalities represent important long-term sequelae of PCOS that warrant further critical investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 269.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ehrmann D. The polycystic ovary syndrome. N Engl J Med 2005;352:1223–1236.

    Article  PubMed  CAS  Google Scholar 

  2. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 1998;51:581–586.

    Article  PubMed  CAS  Google Scholar 

  3. Mather KJ, Kwan F, Corenblum B. Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity. Fertil Steril 2000;73:150–156.

    Article  PubMed  CAS  Google Scholar 

  4. Zimmermann S, Phillips RA, Dunaif A, et al. Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance. J Clin Endocrinol Metab 1992;75:508–513.

    Article  PubMed  CAS  Google Scholar 

  5. Holte J, Pennarelli G, Berne C, Bergh T, Lithell H. Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state? Hum Reprod 1996;11:23–28.

    PubMed  CAS  Google Scholar 

  6. Elting MW, Korsen TJM, Bezemer PD, Schoemaker J. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod 2001;16:556–560.

    Article  PubMed  CAS  Google Scholar 

  7. Pirwany IR, Fleming R, Greer IA, Packard CJ, Sattar N. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol 2001;54:447–453.

    Article  CAS  Google Scholar 

  8. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985;61:946–951.

    Article  PubMed  CAS  Google Scholar 

  9. Harjai KJ. Potential new cardiovascular risk factors: left ventricular hypertrophy, homocysteine, lipoprotein(a), triglycerides, oxidative stress, and fibrinogen. Ann Intern Med 1999;131:376–386.

    PubMed  CAS  Google Scholar 

  10. Davies MJ, Norman RJ. Programming and reproductive functioning. Trends Endocrinol Metab 2002;13:386–392.

    Article  PubMed  CAS  Google Scholar 

  11. Orio F Jr, Palomba S, Spinelli L, et al. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab 2004;89:3696–3701.

    Article  PubMed  CAS  Google Scholar 

  12. Orio F Jr, Palomba S, Cascella T, et al. Early impairment of endothelial structure and function in in young normal-weight women with polycystic ovary yndrome. J Clin Endocrinol Metab 2004;89:4588–4593.

    Article  PubMed  CAS  Google Scholar 

  13. Cibula D, Cifkova R, Fanta M, Poledne R, Zivny J, Skibova J. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod 2000;15:785–789.

    Article  PubMed  CAS  Google Scholar 

  14. Yildiz BO, Haznedaroglu IC, Kirazli S, Bayraktar M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J Clin Endocrinol Metab 2002;87:3871–3875.

    Article  PubMed  CAS  Google Scholar 

  15. Taponen S, Martikainen H, Jarvelin MR, et al. Northern Finland Birth Cohort 1966 Study. Metabolic cardiovascular disease risk factors in women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland Birth Cohort 1966 Study. J Clin Endocrinol Metab 2004;89:2114–2118.

    Article  PubMed  CAS  Google Scholar 

  16. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. Boston: Blackwell Scientific, 1992:377–384.

    Google Scholar 

  17. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25.

    Google Scholar 

  18. Jayagopal V, Kilpatrick ES, Jennings PE, Hepburn DA, Atkin SL. The biological variation of testosterone and sex hormone-binding globulin (SHBG) in polycystic ovarian syndrome: implications for SHBG as a surrogate marker of insulin resistance. J Clin Endocrinol Metab 2003;88:1528–1533.

    Article  PubMed  CAS  Google Scholar 

  19. Talbott EO, Guzick DS, Sutton-Tyrrell K, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000;20:2414–2421.

    PubMed  CAS  Google Scholar 

  20. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 1992;71:599–604.

    PubMed  CAS  Google Scholar 

  21. Amowitz LL, Sobel BE Cardiovascular consequences of polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999;28:439–458.

    Article  PubMed  CAS  Google Scholar 

  22. Bloomgarden ZT. Inflammation and insulin resistance. Diabetes Care 2003;26:1922–1926.

    Article  PubMed  Google Scholar 

  23. Orio F Jr, Palomba S, Spinelli L, et al. The increase of leukocyte as a new marker of low grade chronic inflammation and early cardiovascular risk in the polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:2–5.

    Article  PubMed  CAS  Google Scholar 

  24. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2001;86:2453–2455.

    Article  PubMed  CAS  Google Scholar 

  25. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1929–1935.

    Article  PubMed  CAS  Google Scholar 

  26. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683–689.

    Article  PubMed  CAS  Google Scholar 

  27. Orio F Jr, Palomba S, Di Biase S, et al. Homocysteine levels and C677T polymorphism of methylenetetrahydrofolate reductase in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:673–679.

    Article  PubMed  CAS  Google Scholar 

  28. Yilmaz M, Biri A, Bukan N, et al. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome. Gynecol Endocrinol 2005;20:258–263.

    Article  PubMed  CAS  Google Scholar 

  29. Tarkun I, Arslan BC, Canturk Z, Turemen E, Sahin T, Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 2004;89:5592–5596.

    Article  PubMed  CAS  Google Scholar 

  30. Meade TW, Cooper JA, Chakrabarti R, Miller GJ, Stirling Y, Howarth DJ. Fibrinolityc activity and clotting factor in ischaemic heart disease in women. Br Med J 1996;312:1581.

    CAS  Google Scholar 

  31. Orio F Jr, Palomba S, Cascella T, et al. Is plasminogen activator inhibitor-1 (PAI-1) a cardiovascular risk factor in young women with polycystic ovary syndrome? RBM Online 2004;9:505–510.

    PubMed  CAS  Google Scholar 

  32. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165–169.

    Article  PubMed  CAS  Google Scholar 

  33. Ehrmann D, Barnes R, Rosenfield R, Cavaghan M, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141–146.

    Article  PubMed  CAS  Google Scholar 

  34. Dunaif A. Hyperandrogenic anovulation (PCOS) a unique disorder of insulin action associated with an increased risk of non-insulin dependent diabetes mellitus. Am J Med 1995;98(suppl 1A):1A–33S.

    Google Scholar 

  35. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000;52:595–600.

    Article  CAS  Google Scholar 

  36. Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 2004;59:141–154.

    Article  PubMed  Google Scholar 

  37. Carmina E, Longo RA, Rini GB, Lobo RA. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab 2005;90:2545–2549. [Epub 2005 Feb 22.]

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular and Clinical Endocrinology and Oncology, University “eFederico II,”e, Naples, Italy

    Francesco Orio

  2. Department of Obstetrics and Gynecology, University“eMagna Graecia”e of Catanzaro, Catanzaro, Italy

    Stefano Palomba

Authors
  1. Francesco Orio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefano Palomba
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Center for Androgen Related Disorders, Cedars-Sinai Medical Center; and Department of Obstetrics and Gynecology, and Department of Medicine, The David Geffen School of Medicine at UCLA, Los Angeles, CA

    Ricardo Azziz MD, MPH, MBA

  2. Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA

    John E. Nestler MD

  3. Department of Endocrine Gynaecology and Reproductive Medicine, Lille University Hospital, Lille, France

    Didier Dewailly MD

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Orio, F., Palomba, S. (2006). Hypertension and Cardiovascular and Lipoprotein Abnormalities in the Polycystic Ovary Snydrome. In: Azziz, R., Nestler, J.E., Dewailly, D. (eds) Androgen Excess Disorders in Women. Contemporary Endocrinology. Humana Press. https://doi.org/10.1007/978-1-59745-179-6_29

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-179-6_29

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-663-4

  • Online ISBN: 978-1-59745-179-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation